Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo sinh học: "Careful adjustment of Epo non-viral gene therapy for β-thalassemic anaemia treatment"

Tuyển tập các báo cáo nghiên cứu về sinh học được đăng trên tạp chí sinh học Journal of Biology đề tài: Careful adjustment of Epo non-viral gene therapy for β-thalassemic anaemia treatment | Genetic Vaccines and Therapy BioMed Central Research Careful adjustment of Epo non-viral gene therapy for p-thalassemic anaemia treatment Emmanuelle E Fabre1 2 3 4 Pascal Bigey 1 2 3 4 Yves Beuzard5 Daniel Scherman1 2 3 4 and Emmanuel Payen5 Address 1Unité de Pharmacologie Chimique et Génétique INSERM U640 Faculté de Pharmacie 4 avenue de l observatoire 75006 PariS France 2Unité de Pharmacologie Chimique et Génétique CNRS UMR 8151 Faculté de Pharmacie 4 avenue de l observatoire 75006 Paris France 3Unité de Pharmacologie Chimique et Génétique Université Paris Descartes Faculté de Pharmacie 4 avenue de l observatoire 75006 Paris France 4Unité de Pharmacologie Chimique et Génétique Ecole Nationale Supérieure de Chimie de Paris 11 rue Pierre et Marie Curie 75005 Paris France and 5Laboratoire de Thérapie Génique Hématopoĩétique Institut d Hématologie IUH INSERM U733 Hôpital Saint-Louis 75011 Paris France Email Emmanuelle E Fabre - emma.fabre@gmail.com Pascal Bigey - pascal.bigey@univ-paris5.fr Yves Beuzard - yves.beuzard@sls.aphp.fr Daniel Scherman - daniel.scherman@univ-paris5.fr Emmanuel Payen - letg@jupiter.chu-stlouis.fr Corresponding author Open Access Published II March 2008 Received 12 September 2007 Genetic Vaccines and Therapy 2008 6 10 doi 10.1186 1479-0556-6-10 Accepted 11 March 2008 This article is available from http www.gvt-journal.cOm content 6 1 10 2008 Fabre et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background In situ production of a secreted therapeutic protein is one of the major gene therapy applications. Nevertheless the plasmatic secretion peak of transgenic protein may be deleterious in many gene therapy applications including Epo gene therapy. Epo gene transfer appears to be a .